Biogen (BIIB) Price Target Lifted at BMO Capital; BIIB-037 Opportunity Could Exceed $10B
Tweet Send to a Friend
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on Biogen (NASDAQ: BIIB) to $511.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
